Champlain Investment Partners’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.08M Sell
281,923
-406,859
-59% -$15.1M 0.12% 126
2025
Q4
$29M Sell
688,782
-478,250
-41% -$19.3M 0.29% 107
2025
Q3
$40.1M Buy
+1,167,032
New +$33.5M 0.3% 113
2025
Q1
Sell
-800,355
Closed -$31.7M 149
2024
Q4
$31.7M Sell
800,355
-1,731,125
-68% -$65.5M 0.2% 126
2024
Q3
$86.2M Sell
2,531,480
-636,190
-20% -$17.9M 0.52% 78
2024
Q2
$68.6M Buy
3,167,670
+470,070
+17% +$9.88M 0.42% 92
2024
Q1
$59.8M Buy
2,697,600
+509,340
+23% +$12.4M 0.34% 100
2023
Q4
$60.2M Sell
2,188,260
-115,940
-5% -$2.8M 0.36% 98
2023
Q3
$51.5M Buy
2,304,200
+381,855
+20% +$9.82M 0.33% 104
2023
Q2
$49M Buy
1,922,345
+3,615
+0.2% +$87.6K 0.3% 104
2023
Q1
$42.8M Sell
1,918,730
-37,100
-2% -$897K 0.27% 117
2022
Q4
$46.4M Sell
1,955,830
-65,485
-3% -$1.52M 0.3% 113
2022
Q3
$33.6M Buy
2,021,315
+74,020
+4% +$1.67M 0.23% 118
2022
Q2
$38.8M Buy
1,947,295
+128,990
+7% +$2.61M 0.25% 115
2022
Q1
$50.1M Buy
1,818,305
+50,805
+3% +$1.45M 0.26% 114
2021
Q4
$72.8M Buy
1,767,500
+191,215
+12% +$8.45M 0.33% 108
2021
Q3
$73.2M Buy
1,576,285
+20,725
+1% +$904K 0.35% 108
2021
Q2
$62.2M Buy
1,555,560
+1,001,895
+181% +$42.8M 0.3% 112
2021
Q1
$29.8M Buy
+553,665
New +$31.9M 0.15% 121

Other funds holding VCYT

Champlain Investment Partners's VCYT Position: Q1 2026 in Review

Champlain Investment Partners reduced its Veracyte (VCYT) stake by 59% in Q1 2026, selling an estimated $15.1M and leaving 281,923 shares worth $9.08M. The position accounts for 0.12% of the portfolio, ranked #126.

Champlain Investment Partners first reported a position in VCYT in Q1 2021 and has held it in 19 quarters since. The position peaked at $86.2M in Q3 2024. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • Champlain Investment Partners held 281,923 shares of Veracyte worth $9.08M as of Q1 2026.
  • Champlain Investment Partners sold 406,859 Veracyte shares in Q1 2026, an estimated $15.1M.
  • Veracyte made up 0.12% of Champlain Investment Partners's portfolio in Q1 2026, its #126 holding.
  • Champlain Investment Partners first reported a position in Veracyte in Q1 2021 and has held it in 19 quarters since.
  • Champlain Investment Partners's Veracyte position peaked at $86.2M in Q3 2024.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Champlain Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.